Published in Blood on January 26, 2012
Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood (2012) 1.22
Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood (2014) 1.11
The major histocompatibility complex: a model for understanding graft-versus-host disease. Blood (2013) 1.10
Recombinant structures expand and contract inter and intragenic diversification at the KIR locus. BMC Genomics (2013) 0.98
16th IHIW: international histocompatibility working group in hematopoietic cell transplantation. Int J Immunogenet (2012) 0.88
Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol (2015) 0.84
Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. Biol Blood Marrow Transplant (2016) 0.82
Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. Blood (2016) 0.79
Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation. Haematologica (2013) 0.79
Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP. J Leukoc Biol (2013) 0.77
Genetic risk factors for sclerotic graft-versus-host disease. Blood (2016) 0.77
Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime? Curr Hematol Malig Rep (2015) 0.77
Predicting survival using clinical risk scores and non-HLA immunogenetics. Bone Marrow Transplant (2015) 0.76
Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors. Biol Blood Marrow Transplant (2016) 0.75
A CT60G>A polymorphism in the CTLA-4 gene of the recipient may confer susceptibility to acute graft versus host disease after allogeneic hematopoietic stem cell transplantation. Immunogenetics (2015) 0.75
Recursive organizer (ROR): an analytic framework for sequence-based association analysis. Hum Genet (2013) 0.75
Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target. Front Immunol (2017) 0.75
Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease. Haematologica (2014) 0.75
Microsatellite scanning of the immunogenome associates MAPK14 and ELTD1 with graft-versus-host disease in hematopoietic stem cell transplantation. Immunogenetics (2013) 0.75
SNPs and prognosis of GvHD before HCT: any progress? Bone Marrow Transplant (2015) 0.75
Impact of inflammatory cytokine gene polymorphisms on developing acute graft-versus-host disease in children undergoing allogeneic hematopoietic stem cell transplantation. J Immunol Res (2015) 0.75
SNPs and GVHD prediction: where to next? Blood (2012) 0.75
Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes. Front Immunol (2017) 0.75
Transplant genetics and genomics. Nat Rev Genet (2017) 0.75
Defining vulnerability in allogeneic transplants is more complicated than the two numerical digits of age. Leuk Lymphoma (2015) 0.75
Making the genomic leap in HCT: application of second-generation sequencing to clinical advances in hematopoietic cell transplantation. Eur J Hum Genet (2013) 0.75
Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation. F1000Res (2017) 0.75
Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. Blood (2017) 0.75
Associations of interactions between NLRP3 SNPs and HLA mismatch with acute and extensive chronic graft-versus-host diseases. Sci Rep (2017) 0.75
Association between single nucleotide polymorphisms of tumor necrosis factor gene and grade II-IV acute GvHD: a systematic review and meta-analysis. Bone Marrow Transplant (2017) 0.75
Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet (2006) 115.71
A comprehensive review of genetic association studies. Genet Med (2002) 16.75
Genotype imputation for genome-wide association studies. Nat Rev Genet (2010) 14.59
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest (1998) 6.76
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med (2003) 3.57
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2004) 2.32
Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood (2004) 1.76
Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood (2001) 1.44
Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood (1998) 1.29
Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation (2001) 1.25
CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. Blood (2007) 1.07
NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation. Bone Marrow Transplant (2009) 1.05
Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. Int J Immunogenet (2006) 1.02
IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Hum Immunol (2005) 1.02
Interleukin-6 and interferon-gamma gene polymorphisms in the development of bronchiolitis obliterans syndrome after lung transplantation. Transplantation (2002) 1.02
Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation (2004) 1.00
Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2009) 0.99
Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. J Clin Endocrinol Metab (2004) 0.98
Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation (2003) 0.97
Association of IL6 and CCL2 gene polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant (2009) 0.96
Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. Curr Opin Hematol (2010) 0.96
Polymorphisms of interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol (2003) 0.95
The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. Int J Immunogenet (2008) 0.94
Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation. Bone Marrow Transplant (2008) 0.94
Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant (2000) 0.92
Association of IL-10 and IL-10Rbeta gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor. BMC Immunol (2009) 0.92
HSP70-hom gene polymorphism in allogeneic hematopoietic stem-cell transplant recipients correlates with the development of acute graft-versus-host disease. Transplantation (2005) 0.92
Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant (2006) 0.90
Polymorphism of interleukin-23 receptor gene but not of NOD2/CARD15 is associated with graft-versus-host disease after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant (2009) 0.90
Donor CD31 genotype impacts on transplant complications after human leukocyte antigen-matched sibling allogeneic bone marrow transplantation. Transplantation (2005) 0.89
Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant (2006) 0.89
Polymorphisms of transforming growth factor-beta1 and transforming growth factor-beta1 type II receptor genes are associated with acute graft-versus-host disease in children with HLA-matched sibling bone marrow transplantation. Bone Marrow Transplant (2002) 0.89
Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease. Biol Blood Marrow Transplant (2008) 0.88
High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation. Transplantation (2003) 0.87
Donor CD31 genotype and its association with acute graft-versus-host disease in HLA identical sibling stem cell transplantation. Bone Marrow Transplant (2005) 0.86
Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation. Bone Marrow Transplant (2002) 0.85
Oestrogen receptor alpha gene polymorphism associates with occurrence of graft-versus-host disease and reduced survival in HLA-matched sib-allo BMT. Bone Marrow Transplant (2003) 0.85
Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype. Int J Hematol (2008) 0.84
Polymorphisms in the base excision repair pathway and graft-versus-host disease. Leukemia (2010) 0.84
Genetic variations of interleukin-23R (1143A>G) and BPI (A645G), but not of NOD2, are associated with acute graft-versus-host disease after allogeneic transplantation. Biol Blood Marrow Transplant (2010) 0.84
The interleukin-6 -174promoter polymorphism is associated with long-term kidney allograft survival. Kidney Int (2002) 0.83
Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation. Hum Immunol (2009) 0.82
Cytokine gene polymorphism in patients with graft-versus-host disease. Transplant Proc (2001) 0.81
The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation. Br J Haematol (2002) 0.81
HSP70-hom gene polymorphism as a prognostic marker of graft-versus-host disease. Transplantation (2006) 0.80
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood (2009) 7.00
A fine-scale linkage-disequilibrium measure based on length of haplotype sharing. Am J Hum Genet (2006) 6.02
Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA (2008) 4.19
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med (2008) 4.16
Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis (2007) 3.93
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med (2003) 3.57
The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth. J Clin Invest (2005) 3.56
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood (2002) 3.45
A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med (2003) 3.30
Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis (2004) 3.23
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood (2003) 3.16
The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis. Clin Infect Dis (2013) 3.15
Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis (2004) 3.01
Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med (2010) 3.01
Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science (2010) 2.99
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol (2008) 2.99
Seasonal patterns in monthly hemoglobin A1c values. Am J Epidemiol (2005) 2.93
Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med (2006) 2.85
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83
Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood (2004) 2.83
Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood (2004) 2.77
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood (2009) 2.73
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol (2007) 2.66
Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA (2004) 2.65
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Age group and sex differences in performance on a computerized neurocognitive battery in children age 8-21. Neuropsychology (2012) 2.54
Public stem cell banks: considerations of justice in stem cell research and therapy. Hastings Cent Rep (2004) 2.53
Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.49
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood (2007) 2.49
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant (2006) 2.44
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood (2009) 2.44
Flavonoids: promising anticancer agents. Med Res Rev (2003) 2.43
Cas5d protein processes pre-crRNA and assembles into a cascade-like interference complex in subtype I-C/Dvulg CRISPR-Cas system. Structure (2012) 2.42
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol (2005) 2.41
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood (2003) 2.40
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood (2008) 2.39
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2004) 2.32
Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst (2003) 2.29
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood (2004) 2.28
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis (2008) 2.27
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood (2011) 2.26
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood (2013) 2.23
Gene expression analyzed by high-resolution state array analysis and quantitative proteomics: response of yeast to mating pheromone. Mol Cell Proteomics (2004) 2.22
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood (2013) 2.22
Prehypertension and black-white contrasts in cardiovascular risk in young adults: Bogalusa Heart Study. J Hypertens (2009) 2.20
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis (2011) 2.19
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood (2012) 2.19
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant (2008) 2.15
Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol (2005) 2.11
A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis (2012) 2.08
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol (2010) 2.07
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol (2005) 2.04
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood (2003) 2.01
A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood (2012) 2.00
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood (2010) 1.97
Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem (2003) 1.97
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant (2008) 1.96
An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood (2006) 1.95
Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood (2013) 1.94
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood (2003) 1.93
High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis (2002) 1.93
ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest (2008) 1.92
Estimating haplotype frequencies and standard errors for multiple single nucleotide polymorphisms. Biostatistics (2003) 1.91
A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med (2006) 1.91
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood (2011) 1.90
Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion (2002) 1.89
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood (2010) 1.88
Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood (2007) 1.85